Sarepta's 84-week data show continued eteplirsen efficacy
This article was originally published in Scrip
Executive Summary
With little new guidance on accelerated US FDA approval for the Duchenne muscular dystrophy (DMD) therapy eteplirsen, Sarepta Therapeutics investors gave the company's stock a 4.3% boost on 19 June based on the next best thing: additional long-term safety and efficacy data for the exon-skipping drug.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.